The DLEC1 Polyclonal Antibody (PACO05850) is a valuable tool for researchers studying DLEC1, a tumor suppressor gene involved in the regulation of cell growth and differentiation. This antibody, produced in rabbits, exhibits high reactivity with human samples and has been validated for use in Western blot applications. By binding specifically to the DLEC1 protein, this antibody enables accurate detection and analysis in various cell types, making it an essential component of studies in cancer biology and tumor progression.DLEC1, also known as Deleted in Lung and Esophageal Cancer 1, plays a crucial role in suppressing tumor formation and progression by inhibiting cell proliferation and promoting apoptosis.
Its importance in regulating cellular processes makes it a promising target for research aimed at understanding the molecular mechanisms underlying cancer development and progression. By elucidating the functions of DLEC1, researchers can uncover new insights into the pathogenesis of various types of cancer and potentially identify novel therapeutic strategies targeting this tumor suppressor gene.
Antibody Name:
DLEC1 Antibody (PACO05850)
Antibody SKU:
PACO05850
Size:
50ug
Host Species:
Rabbit
Tested Applications:
ELISA, IHC, IF
Recommended Dilutions:
ELISA:1:10000, IHC:1:100-1:300, IF:1:200-1:1000
Species Reactivity:
Human
Immunogen:
Synthesized peptide derived from the N-terminal region of human DLEC1.
Form:
Liquid
Storage Buffer:
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Purification Method:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Clonality:
Polyclonal
Isotype:
IgG
Conjugate:
Non-conjugated
Synonyms:
DLEC1; DLC1; Deleted in lung and esophageal cancer protein 1; Deleted in lung cancer protein 1; DLC-1
UniProt Protein Function:
DLEC1: May act as a tumor suppressor by inhibiting cell proliferation. DLEC1 silencing due to promoter methylation and aberrant transcription are implicated in the development of different cancers, including esophageal (ESCR), renal and lung cancers (LNCR). Defects in DLEC1 are a cause of lung cancer (LNCR). A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. DLEC1 silencing due to promoter methylation and aberrant transcription are implicated in the development of lung cancer. Defects in DLEC1 are a cause of esophageal cancer (ESCR). A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage. DLEC1 silencing due to promoter methylation and aberrant transcription are implicated in the development of esophageal cancer. 3 isoforms of the human protein are produced by alternative splicing.Protein type: Tumor suppressorChromosomal Location of Human Ortholog: 3p21.3Cellular Component: cytoplasmDisease: Esophageal Cancer; Lung Cancer
UniProt Protein Details:
NCBI Summary:
The cytogenetic location of this gene is 3p21.3, and it is located in a region that is commonly deleted in a variety of malignancies. Down-regulation of this gene has been observed in several human cancers including lung, esophageal, renal tumors, and head and neck squamous cell carcinoma. In some cases, reduced expression of this gene in tumor cells is a result of aberrant promoter methylation. Several alternatively spliced transcripts have been observed that contain disrupted coding regions and likely encode nonfunctional proteins.[provided by RefSeq, Mar 2016]